Last reviewed · How we verify
Any topical drug treatment
Calcineurin inhibitor
Calcineurin inhibitor Used for Atopic dermatitis.
At a glance
| Generic name | Any topical drug treatment |
|---|---|
| Also known as | Non-drug topicals |
| Sponsor | LEO Pharma |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Calcineurin inhibitors are a class of drugs that block the action of calcineurin, a protein phosphatase involved in the activation of T cells. By inhibiting calcineurin, these drugs reduce the production of pro-inflammatory cytokines and prevent the activation of T cells.
Approved indications
- Atopic dermatitis
Common side effects
- Hypersensitivity reaction
- Skin burning sensation
- Headache
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Pharmacokinetics of Transdermal Metronidazole (PHASE4)
- Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma (PHASE2)
- Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (PHASE4)
- A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients (EARLY_PHASE1)
- Fractional CO2 Laser-assisted Delivery of Hyaluronic Acid, Ascorbic Acid and Sodium DNA For Enhancing Facial Skin Quality in Individuals Over the Age of 30 (PHASE4)
- Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Any topical drug treatment CI brief — competitive landscape report
- Any topical drug treatment updates RSS · CI watch RSS
- LEO Pharma portfolio CI